Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04870281 · ClinicalTrials.gov registry record
Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System
A clinical trial, sponsored by Biotronik.
- Terminated
- Registry status
- 13
- Enrollment target
NCT04870281: Clinical Trial study, sponsored by Biotronik.
NCT04870281 is a clinical trial that was terminated before completion, run by Biotronik. The registered enrollment target is 13 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04870281 was terminated before completion, sponsored by Biotronik.
- TERMINATED
- Registry status
- 13 participants
- Enrollment target
Study Summary
The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
Interventions
- DEVICE CRT-DX
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2021-05-28 |
| Est. Completion | 2021-12-29 |
Why NCT04870281 stopped before completion
NCT04870281 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 13 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which CRT-DX is the first listed.
NCT04870281 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04870281 about?
NCT04870281 is a clinical study titled "Atrial Fibrillation Associated With Heart Failure Treated by BIOTRONIK's CRT-DX System". The purpose of the BIO-AffectDX Study is to prospectively evaluate improvement from baseline in heart failure subjects with atrial fibrillation (AF) implanted with a two-lead CRT-DX system, with emphasis on a comparison of patient outcomes between AF subtypes.
What is the current status of trial NCT04870281?
This trial is currently terminated. The enrollment target is 13 participants. The study started on 2021-05-28. Estimated completion is 2021-12-29.
What interventions are being tested in trial NCT04870281?
The interventions under investigation include: CRT-DX (DEVICE).
Who is sponsoring clinical trial NCT04870281?
This trial is sponsored by Biotronik, which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI